CIK 0001070081
- Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043416587
- Phone
- +1 908-222-7000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,548,017
- in 9 filings, $7.5M under 10b5-1 plans
Net −$7,548,017. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −45,392 | $53.15 | $2.4M | 103,901 |
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +11,398 | $33.02 | $376K | 115,299 |
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −11,398 | $53.12 | $605K | 103,901 |
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +11,249 | $25.69 | $289K | 115,150 |
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −3,487 | $52.24 | $182K | 111,663 |
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −7,762 | $53.05 | $412K | 103,901 |
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −45,392 | 18,788 | ||
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,398 | 4,114 | ||
| 2025-03-10 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,249 | 33,751 | ||
| 2025-03-04 | Jacobson Allan Steven Director | Sale | −1,230 | $51.52 | $63K | 19,118 |
| 2025-02-20 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −878 | $50.12 | $44K | 62,564 |
| 2025-02-20 | Gravier Pierre CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,167 | $50.12 | $58K | 74,436 |
| 2025-02-20 | Pauwels Eric CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −1,567 | $50.12 | $79K | 83,860 |
| 2025-02-20 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −3,895 | $50.12 | $195K | 276,038 |
| 2025-02-20 | Golden Lee Scott EVP & CHIEF MEDICAL OFFICER | Sale 10b5-1 | −962 | $50.12 | $48K | 76,894 |
| 2025-02-20 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,614 | $50.12 | $81K | 103,901 |
| 2025-02-20 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −1,578 | $50.12 | $79K | 100,353 |
| 2025-02-20 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −34 | $50.12 | $2K | 5,907 |
| 2025-02-19 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −879 | $50.10 | $44K | 63,442 |
| 2025-02-19 | Gravier Pierre CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,168 | $50.10 | $59K | 75,603 |
Page 27 of 41 · 804 trades